NovaBay Pharmaceuticals, Inc. Signs Option Agreement With Virbac Corporation Animal Health for Aganocide(R) Compounds

EMERYVILLE, Calif., March 20, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company today announced that it has entered into a feasibility and option agreement with Virbac Animal Health for the development and potential commercialization of Aganocides for a number of veterinary uses. NovaBay is developing its first-in-class, non-antibiotic, anti-infective Aganocide® compounds for the topical treatment and prevention of a wide variety of bacterial, viral and fungal infections.

Back to news